Literature DB >> 9558037

Inhibition of human gastric lipase secretion by glucagon-like peptide-1.

M Wøjdemann1, A Wettergren, B Sternby, J J Holst, S Larsen, J F Rehfeld, O Olsen.   

Abstract

Glucagon-like peptide-1 (GLP-1) may be one of the enterogastrone hormones of the ileal brake mechanism. We therefore studied its effects on gastric lipase secretion in healthy volunteers and vagotomized patients during infusion of pentagastrin. The intestinal incretin hormone GLP-1 (glucagon-like peptide-1, 7-36 amide) was investigated because of its inhibitory effects on gastric acid secretion and motility. GLP-1 infused intravenously in amounts corresponding to the postprandial release significantly inhibited pentagastrin-stimulated gastric lipase secretion and lipolytic activity. The inhibitory effect of GLP-1 persisted in vagotomized patients, suggesting that fundic chief cells, from which gastric lipase is released, or neighboring inhibitory cells could be equipped with GLP-1 receptors. Vagotomized patients had significantly higher plasma concentrations of gastrin and secretin. No significant changes of gastrin, secretin, and CCK secretion were seen during GLP-1 infusion in the vagotomized patients, whereas secretin decreased significantly in the healthy volunteers. GLP-1 seems to be a naturally occurring inhibitor of gastric lipase secretion acting via a nonvagal mechanism. Our results indicate that gastric lipase secretion is subject to hormonal stimulatory as well as inhibitory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558037     DOI: 10.1023/a:1018874300026

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Evaluation of a radioimmunoassay for cholecystokinin in human plasma.

Authors:  P Cantor
Journal:  Scand J Clin Lab Invest       Date:  1986-05       Impact factor: 1.713

2.  Production and evaluation of antibodies for the radioimmunoassay of gastrin.

Authors:  J F Rehfeld; F Stadil; B Rubin
Journal:  Scand J Clin Lab Invest       Date:  1972-10       Impact factor: 1.713

3.  Gastric lipase secretion after sham feeding and cholinergic blockade.

Authors:  M Wøjdemann; O Olsen; P Nørregaard; B Sternby; J F Rehfeld
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

4.  Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells.

Authors:  A Rai; G Singh; R Raffaniello; J Eng; J P Raufman
Journal:  Am J Physiol       Date:  1993-07

5.  Meal-stimulated secretin release in man: effect of acid and bile.

Authors:  O B Schaffalitzky de Muckadell; J Fahrenkrug; J Nielsen; I Westphall; H Worning
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

6.  Deficient gastric lipase secretion in pancreatic insufficiency.

Authors:  M Wøjdemann; O Olsen; S Larsen; B Sternby; J F Rehfeld
Journal:  Scand J Gastroenterol       Date:  1997-03       Impact factor: 2.423

7.  Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.

Authors:  C Orskov; A Wettergren; J J Holst
Journal:  Scand J Gastroenterol       Date:  1996-07       Impact factor: 2.423

8.  Kinetic assay of human gastric lipase on short- and long-chain triacylglycerol emulsions.

Authors:  Y Gargouri; G Pieroni; C Riviere; J F Sauniere; P A Lowe; L Sarda; R Verger
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

9.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

Authors:  R M Elliott; L M Morgan; J A Tredger; S Deacon; J Wright; V Marks
Journal:  J Endocrinol       Date:  1993-07       Impact factor: 4.286

Review 10.  Glucagonlike peptide 1: a newly discovered gastrointestinal hormone.

Authors:  J J Holst
Journal:  Gastroenterology       Date:  1994-12       Impact factor: 22.682

View more
  9 in total

1.  The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes.

Authors:  Hirokazu Kakuda; Junji Kobayashi; Masahiro Kakuda; Junichi Yamakawa; Noboru Takekoshi
Journal:  Endocrine       Date:  2014-08-13       Impact factor: 3.633

Review 2.  Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials.

Authors:  Amir Hadi; Ehsan Ghaedi; Saman Khalesi; Makan Pourmasoumi; Arman Arab
Journal:  Eur J Nutr       Date:  2020-04-22       Impact factor: 5.614

3.  Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.

Authors:  J J Meier; A Gethmann; O Götze; B Gallwitz; J J Holst; W E Schmidt; M A Nauck
Journal:  Diabetologia       Date:  2006-01-31       Impact factor: 10.122

Review 4.  The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia.

Authors:  Peter Novodvorský; Martin Haluzík
Journal:  Curr Atheroscler Rep       Date:  2022-01-24       Impact factor: 5.113

5.  Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.

Authors:  Yoko Noda; Toru Miyoshi; Hiroki Oe; Yuko Ohno; Kazufumi Nakamura; Norihisa Toh; Kunihisa Kohno; Hiroshi Morita; Kengo Kusano; Hiroshi Ito
Journal:  Cardiovasc Diabetol       Date:  2013-01-09       Impact factor: 9.951

6.  Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals.

Authors:  Kaoru Noguchi; Minoru Hirota; Toru Miyoshi; Yoshinori Tani; Yoko Noda; Hiroshi Ito; Seiji Nanba
Journal:  Exp Ther Med       Date:  2014-11-05       Impact factor: 2.447

7.  GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions.

Authors:  Ji Hee Yu; So Young Park; Da Young Lee; Nan Hee Kim; Ji A Seo
Journal:  Kidney Res Clin Pract       Date:  2022-03-25

8.  Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.

Authors:  Miyako Kishimoto
Journal:  Diabetes Metab Syndr Obes       Date:  2013-05-06       Impact factor: 3.168

9.  Gastric lipase secretion in children with gastritis.

Authors:  Przemyslaw J Tomasik; Andrzej Wędrychowicz; Iwona Rogatko; Andrzej Zając; Krzysztof Fyderek; Krystyna Sztefko
Journal:  Nutrients       Date:  2013-07-29       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.